Values as of: 2025-05-23
COMMON STOCK | Biotechnology |
Last Closing
USD 86.7Change
-2.10 (-2.36)%Market Cap
USD 21.41BVolume
45.00Analyst Target
N/AVerdict
Verdict
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Company Website : https://www.biontech.de
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| CSJA:F | CSL LTD SPON.ADR 2 |
+0.50 (+0.73%) |
USD 67.81B |
| CSJ:F | CSL Limited |
-1.00 (-0.72%) |
USD 67.05B |
| RGO:F | Regeneron Pharmaceuticals Inc |
-20.40 (-3.80%) |
USD 58.84B |
| 1AEA:F | argenx SE |
-5.00 (-0.98%) |
USD 36.54B |
| DUL:F | Alnylam Pharmaceuticals Inc |
-3.40 (-1.33%) |
USD 35.18B |
| 1AE:F | Argen-X |
+1.80 (+0.35%) |
USD 34.68B |
| UNC0:F | UCB S.A. UNSP.ADR 1/2 |
-1.00 (-1.25%) |
USD 27.89B |
| 49B:F | BeiGene Ltd. |
+0.26 (+1.62%) |
USD 26.89B |
| 49BA:F | BeiGene Ltd |
N/A |
USD 25.20B |
| RPD:F | ROYALTY PHARMA OA DL-0001 |
-0.78 (-2.69%) |
USD 16.36B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -20.24% | 42% | F | 21% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -20.24% | 42% | F | 20% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -1.64% | 62% | D | 50% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -1.64% | 62% | D | 44% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 82.53% | 87% | B+ | 71% | C- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 82.53% | 85% | B | 54% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 33.38% | 85% | B | 90% | A- | ||
| Dividend Return | 33.38% | 85% | B | 84% | B | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 115.78% | 12% | F | 10% | F | ||
| Risk Adjusted Return | 28.83% | 77% | C+ | 52% | F | ||
| Market Capitalization | 21.41B | 98% | N/A | 91% | A- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
